Excimer Light(308) Therapy for Resistant Alopecia Areata

Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID

Study Details

Study Description

Brief Summary

This study aimed to evaluate the efficacy and safety of the 308-nm excimer lamp in resistant AA treated with topical minoxidil .

Condition or Disease Intervention/Treatment Phase
  • Device: excimer light

Detailed Description

Alopecia areata (AA) is a chronic, nonscarring, T-cell mediated autoimmune disease, presenting with localized or diffuse hair fall in hair-bearing areas. Approximately 1.7% of the population experience an episode of AA during their lifetime. Both sexes are equally affected, and most new cases are recorded below the age of 30 years . Excimer laser using high-dose monochromatic UV radiation can trigger apoptosis and induce immunological suppression through altering cytokine production such as IL-4, IL-10, prostaglandin E2, platelet-activating factor, and cis-urocanic acid. Benefits have only been seen with localized patches of AA, and regrowth of hair occurs only in treated areas .

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
20 participants
Observational Model:
Time Perspective:
Official Title:
Efficacy of Excimer Light(308) Therapy for Resistant Alopecia Areata
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Nov 30, 2024
Anticipated Study Completion Date :
Dec 30, 2024

Outcome Measures

Primary Outcome Measures

  1. alopecia areata with ecimer light [3 months]

    evulate patients monthly during treatment with excimer light and minoxidil gel for three months With 20 patients who should completely recovered from alopecia areata.

Eligibility Criteria


Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
Inclusion Criteria:
  • ● Having multiple patches of AA.

  • Duration of alopecia >1 year

  • No topical or systemic treatment for the last 4 months

  • Agreement to regular visits for treatment and follow-up.

Exclusion Criteria:
  • ● A single form of AA.

  • Alopecia for <1 year.

  • Being on other modalities of treatment.

  • Treatment within the last 4 months.

  • Photosensitive disorders.

  • Pregnancy or breastfeeding.

Contacts and Locations


No locations specified.

Sponsors and Collaborators

  • Assiut University


None specified.

Study Documents (Full-Text)

None provided.

More Information


None provided.
Responsible Party:
Hagar Maher, doctor, Assiut University
ClinicalTrials.gov Identifier:
Other Study ID Numbers:
  • alopecia areata with excimer
First Posted:
Nov 29, 2023
Last Update Posted:
Nov 29, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
Studies a U.S. FDA-regulated Device Product:
Keywords provided by Hagar Maher, doctor, Assiut University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 29, 2023